Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 analysis

Table 3 Incidence of adverse reactions during treatment in the two groups

Group	HFSR	Anemia	Hepatic insufficiency	Weakness	Nausea and vomiting	Neutropenia
Observation group (n = 47)	10 (21.28)	2 (4.26)	2 (4.26)	7 (14.89)	14 (29.79)	14 (29.79)
Control group (n = 47)	9 (19.15)	1 (2.13)	2 (4.26)	5 (10.64)	12 (25.53)	12 (25.53)
χ2	0.066	0	0.261	0.382	0.213	0.213
P value	0.797	1	0.609	0.536	0.645	0.645

HFSR: Hand-foot skin reaction.